Re: Clover et al. Transformation of a non-secretory neuro-endocrine tumor to insulinoma after treatment with Sunitinib: a case report and review of the literature. J Oncol Pharm Pract 2018. DOI: 10.1177/1078155218791309

Abstract

Get full access to this article

View all access options for this article.

References

Clover T, Abdelkader A and Guru Murthy GS. Transformation of a non-secretory neuro-endocrine tumor to insulinoma after treatment with Sunitinib: a case report and review of the literature. J Oncol Pharm Pract 2018 Aug 8:1078155218791309. doi: 10.1177/1078155218791309.

Fountas

Tigas

Giotaki

et al.

Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones (Athens) 2015; 14: 438–441.

Fountas

Diamantopoulos

Tsatsoulis

. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab 2015; 26: 643–656.

Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/study/NCT01781975 (accessed 25 September 2018).